Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Nuvation Bio logo
Nuvation BioNUVB
$5.07M+112%

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
Relmada Therapeutics, Inc. (RLMD) reported cash provided by (used in) operating activity, including discontinued operation of -$15.07M in Q1 2026.
How has Relmada Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Relmada Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation increased by 16.6% year-over-year, from -$18.07M to -$15.07M.
What is the long-term trend for Relmada Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s cash provided by (used in) operating activity, including discontinued operation has grown at a -16.0% compound annual growth rate (CAGR), from -$91.87M to -$45.79M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.